- Current report filing (8-K)

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  August 13, 2010

 

TIENS BIOTECH GROUP (USA), INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware		001-32477		75-2926439
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification Number)

 

No. 6, Yuanquan Road, Wuqing New-Tech Industrial Park, Tianjin, China 301700

 

(Address of principal executive offices)

 

Registrant's telephone number, including area code: （ 86 ） 22 - 8213- 7335

 

Not applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

 

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.02                      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 13, 2010, the Board of Directors of Tiens Biotech Group (USA), Inc. (the “Company”) appointed Jinyuan Li, Chairman, Chief Executive Officer and President of the Company, as Acting Chief Financial Officer of the Company to fill the vacancy created by the resignation of Manbo He, the Company’s former Chief Financial Officer, who resigned on June 17, 2010.

 

Other information required by this Item regarding Mr. Li is omitted, as it has been previously reported.

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	TIENS BIOTECH GROUP (USA), INC.
Date:  August 17, 2010	By:	/s/ Jinyuan Li
		Name:   Jinyuan Li
		Title:    Chairman, Chief Executive Officer and President

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3